On the path to 2025

• Verfasst von: Aisen, Paul S. [VerfasserIn]
• Verfasst von: Frölich, Lutz [VerfasserIn]
• Titel: On the path to 2025
• Titelzusatz: understanding the Alzheimer’s disease continuum
• Verf.angabe: Paul S. Aisen, Jeffrey Cummings, Clifford R. Jack, John C. Morris, Reisa Sperling, Lutz Frölich, Roy W. Jones, Sherie A. Dowsett, Brandy R. Matthews, Joel Raskin, Philip Scheltens and Bruno Dubois
• Jahr: 2017
• Umfang: 10 S.
• Fussnoten: Published: 9 August 2017 ; Gesehen am 19.06.2018
• Titel Quelle: Enthalten in: Alzheimer's research & therapy
• Ort Quelle: London : BioMed Central, 2009
• Jahr Quelle: 2017
• Band/Heft Quelle: 9(2017) Artikel-Nummer 60, 10 Seiten
• ISSN Quelle: 1758-9193
• DOI: doi:10.1186/s13195-017-0283-5
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Alzheimer’s disease
• Sach-SW: Amyloid beta
• Sach-SW: Biomarker
• Sach-SW: Clinical
• Sach-SW: Cognitive impairment
• Sach-SW: Continuum
• Sach-SW: Dementia
• Sach-SW: Tau
• K10plus-PPN: 1576537587

Abstract

Basic research advances in recent years have furthered our understanding of the natural history of Alzheimer’s disease (AD). It is now recognized that pathophysiological changes begin many years prior to clinical manifestations of disease and the spectrum of AD spans from clinically asymptomatic to severely impaired. Defining AD purely by its clinical presentation is thus artificial and efforts have been made to recognize the disease based on both clinical and biomarker findings. Advances with biomarkers have also prompted a shift in how the disease is considered as a clinico-pathophysiological entity, with an increasing appreciation that AD should not only be viewed with discrete and defined clinical stages, but as a multifaceted process moving along a seamless continuum. Acknowledging this concept is critical to understanding the development process for disease-modifying therapies, and for initiating effective diagnostic and disease management options. In this article, we discuss the concept of a disease continuum from pathophysiological, biomarker, and clinical perspectives, and highlight the importance of considering AD as a continuum rather than discrete stages. While the pathophysiology of AD has still not been elucidated completely, there is ample evidence to support researchers and clinicians embracing the view of a disease continuum in their study, diagnosis, and management of the disease.